Glioma Response to IDH Inhibition: Real-World Experience.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
13
08
2023
revised:
28
08
2023
accepted:
07
09
2023
medline:
4
12
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors. See related article by Kamson et al., p. 4863.
Identifiants
pubmed: 37738033
pii: 729226
doi: 10.1158/1078-0432.CCR-23-2164
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4709-4710Subventions
Organisme : National Cancer Institute (NCI)
ID : P50CA221747
Informations de copyright
©2023 American Association for Cancer Research.